BioSpace News Archive

ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, is pleased to announce that its common shares are now trading on the OTCQB Venture Market. We believe that graduating to the OTCQB Venture Market is an important step for the company’s future and that it will bring better visibility and liquidity within the investment community. The OTCQB Venture Market is well suited for developing companies. To b

Health Canada recently announced the Dexcom G6 Continuous Glucose Monitoring system has been temporarily authorized for expanded use in hospitals, in an effort to help remotely monitor those who are critically ill during the COVID-19 pandemic.

Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the appointment of Dr. Geoff Cotton, MB BS, MBA to its Board of Directors. Dr. Cotton is a healthcare executive, venture capital adviser, and angel investor with 20 years experience in the pharmaceutical industry. He spent over 17 years with Gilead Sciences Inc. in Medical Affairs and Commercial roles of increasing responsibility culminating in leadership of the Glo

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 11, 2020 to report its first quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-971

Seelos Therapeutics, Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for Seelos’ U.S. patent number 10,437,637 titled “COMPOSITIONS AND METHODS FOR TREATING AN AGGREGATION DISEASE OR DISORDER” for trehalose.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for Monday, May 11, 2020. The schedule for the press release and conference call/webcast are as follows: • Q1 2020 Press Release: May 11, 2020 at 6:00 a.m. ET • Q1 2020 Conference Call/Webcast: May 11, 2020 at 8:00 a.m. ET • Do

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release first quarter 2020 financial results after market close on Monday, May 11, 2020. Further, Catalyst management will host an investment-community conference cal

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Paul Stickler as the company’s new Senior Vice President of Sales and Marketing. Stickler brings more than twenty-five years of pharmaceutical sales and marketing experience with a primary focus in orphan and neurology products. In the new role, he will be responsi

Surgical navigation startup Centerline Biomedical, Inc. (Centerline), a Cleveland Clinic spin-off company, has announced the successful completion of the first in a series clinical cases in the US

Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus.